Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R P Perez

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Military Medicine|December 1, 1999
Development of a core curriculum in professional growth: practice management military modelR P Perez, F B Brown, E R Salminen, et al.
Biochemical Pharmacology|July 12, 1996
Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell linesP J O'Dwyer, R P Perez, K S Yao, et al.
International Journal of Cancer|May 10, 1991
Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell linesR P Perez, P J O'Dwyer, L M Handel, et al.
Gynecologic Oncology|September 1, 1995
Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cellsR P Perez, S W Johnson, L M Handel, et al.
Investigational New Drugs|July 1, 1992
Phase II study of amonafide in advanced and recurrent sarcoma patientsR P Perez, S L Nash, R F Ozols, et al.
The American Journal of Medicine|June 1, 1990
AIDS and Chagas' disease with central nervous system tumor-like lesionM Del Castillo, G Mendoza, J Oviedo, et al.
Cancer Research|August 15, 1993
Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivityR P Perez, K Hamaguchi, P A Tracey, et al.
Seminars in Oncology|December 1, 1996
Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumorsP J Creaven, D Raghavan, R P Perez, et al.
Biochemical Pharmacology|February 11, 1994
Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell linesS W Johnson, R P Perez, A K Godwin, et al.
Cancer Research|February 1, 1994
Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 scheduleR J Schilder, F P LaCreta, R P Perez, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Military Medicine|December 1, 1999
Development of a core curriculum in professional growth: practice management military modelR P Perez, F B Brown, E R Salminen, et al.
Biochemical Pharmacology|July 12, 1996
Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell linesP J O'Dwyer, R P Perez, K S Yao, et al.
International Journal of Cancer|May 10, 1991
Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell linesR P Perez, P J O'Dwyer, L M Handel, et al.
Gynecologic Oncology|September 1, 1995
Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cellsR P Perez, S W Johnson, L M Handel, et al.
Investigational New Drugs|July 1, 1992
Phase II study of amonafide in advanced and recurrent sarcoma patientsR P Perez, S L Nash, R F Ozols, et al.
The American Journal of Medicine|June 1, 1990
AIDS and Chagas' disease with central nervous system tumor-like lesionM Del Castillo, G Mendoza, J Oviedo, et al.
Cancer Research|August 15, 1993
Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivityR P Perez, K Hamaguchi, P A Tracey, et al.
Seminars in Oncology|December 1, 1996
Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumorsP J Creaven, D Raghavan, R P Perez, et al.
Biochemical Pharmacology|February 11, 1994
Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell linesS W Johnson, R P Perez, A K Godwin, et al.
Cancer Research|February 1, 1994
Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 scheduleR J Schilder, F P LaCreta, R P Perez, et al.
Pageof 4